March 25
nrsg265 Exam Complete Questions and Correct Detailed
Answers (Verified Answers)
Type 1 DM
Ans: due to beta cell destruction which causes severe insulin deficiency which leads
to hyperglycaemia
type 2 diabetes
Ans: high blood glucose resulting from impaired insulin utilization coupled with the
body's inability to compensate with increased insulin production.
type 1 diabetes signs and symptoms
pg. 1
, March 25
Ans: initial
- fatigue
-weight loss
-blurred vision
-confusion
Late signs
- nausea and vomiting
-abdo pain
-tachycardic
-ketonic breath
-seizures
-coma
Type 1 treatment
Ans: insulin
Type 1 pathophysiology
Ans: the culmination of lymphocytic infiltration and destruction of insulin-secreting
beta cells of the islets of Langerhans in the pancreas.
Type 2 Pathophysiology
pg. 2
, March 25
Ans: -insulin resistance
-impaired insulin secretion (decreased secretion or faulty release/timing issue)
-excessive hepatic glucose production
-syndrome x
Type 2 clinical manifestations
Ans: 3 P's - polyphagia, polyuria, polydipsia
fatigue
hyperglycaemia
late signs
repeated infections
poor wound healing
blurred vision
weight changes
Type 2 drugs
Ans: Metformin, sulfonylurea,
Bigunides (Metformin)
Ans: MOA: decreases hepatic release of glucose
Decreases intestinal absorption of glucose
Improves insulin sensitivity by increasing peripheral uptake of glucose
pg. 3
nrsg265 Exam Complete Questions and Correct Detailed
Answers (Verified Answers)
Type 1 DM
Ans: due to beta cell destruction which causes severe insulin deficiency which leads
to hyperglycaemia
type 2 diabetes
Ans: high blood glucose resulting from impaired insulin utilization coupled with the
body's inability to compensate with increased insulin production.
type 1 diabetes signs and symptoms
pg. 1
, March 25
Ans: initial
- fatigue
-weight loss
-blurred vision
-confusion
Late signs
- nausea and vomiting
-abdo pain
-tachycardic
-ketonic breath
-seizures
-coma
Type 1 treatment
Ans: insulin
Type 1 pathophysiology
Ans: the culmination of lymphocytic infiltration and destruction of insulin-secreting
beta cells of the islets of Langerhans in the pancreas.
Type 2 Pathophysiology
pg. 2
, March 25
Ans: -insulin resistance
-impaired insulin secretion (decreased secretion or faulty release/timing issue)
-excessive hepatic glucose production
-syndrome x
Type 2 clinical manifestations
Ans: 3 P's - polyphagia, polyuria, polydipsia
fatigue
hyperglycaemia
late signs
repeated infections
poor wound healing
blurred vision
weight changes
Type 2 drugs
Ans: Metformin, sulfonylurea,
Bigunides (Metformin)
Ans: MOA: decreases hepatic release of glucose
Decreases intestinal absorption of glucose
Improves insulin sensitivity by increasing peripheral uptake of glucose
pg. 3
